Vimarsana
Biggest News Aggregation in the World

Chikita News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chikita. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chikita Today - Breaking & Trending Today

PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine - Vimarsana News

PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine

PharmaDrug Inc. , a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously...

PharmaDrug Inc.: PharmaDrug Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer - Vimarsana News

PharmaDrug Inc.: PharmaDrug Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer

Toronto, Ontario--(Newsfile Corp. - February 13, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development

PharmaDrug Inc.: PharmaDrug Advances Programs in Oncology with Filing of PCT Application Detailing the Use of PD-001 for Treatment of Prostate Cancer - Vimarsana News

PharmaDrug Inc.: PharmaDrug Advances Programs in Oncology with Filing of PCT Application Detailing the Use of PD-001 for Treatment of Prostate Cancer

Toronto, Ontario--(Newsfile Corp. - January 31, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development

PharmaDrug Inc.: PharmaDrug Successfully Completes Key Milestone to Support cGMP Production of Clinical Lead Candidate PD-001, Its Patented, Orally Available Version of Cepharanthine for Oncology and Infectious Disease - Vimarsana News

PharmaDrug Inc.: PharmaDrug Successfully Completes Key Milestone to Support cGMP Production of Clinical Lead Candidate PD-001, Its Patented, Orally Available Version of Cepharanthine for Oncology and Infectious Disease

Completes qualification of all necessary analytical methodologies to support production of Cepharanthine-2HCL drug substanceClinical trial-scale production of cGMP Cepharanthine-2HCL drug substance scheduled

PharmaDrug Inc.: PharmaDrug Announces Positive Findings for the Combination of Cepharanthine and Frontline Chemotherapy for IND-Enabling Esophageal Cancer Study - Vimarsana News

PharmaDrug Inc.: PharmaDrug Announces Positive Findings for the Combination of Cepharanthine and Frontline Chemotherapy for IND-Enabling Esophageal Cancer Study

Results show that oral cepharanthine plus paclitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 28, the final day of dosing compared to paclitaxel